Table 3.
Apolipoprotein B and β2-glycoprotein-I (GPI) autoantibodies in systemic lupus erythematosus (SLE) patients with and without cardiovascular disease
| SLE |
||||
|---|---|---|---|---|
| CVD (n = 62) median (IQR)* | No CVD (n = 370) median (IQR)* | P | P adjusted | |
| Apo B antibodies | ||||
| p45 IgM | 0·47 (0·19–1·17) | 0·70 (0·33–1·29) | 0·01 | n.s. |
| MDA-p45 IgM | 0·55 (0·24–1·02) | 0·75 (0·41–1·48) | 0·003 | 0·04 |
| p45 IgG | 0·36 (0·17–0·90) | 0·54 (0·23–1·05) | n.s. | n.s. |
| MDA-p45 IgG | 0·46 (0·29–0·84) | 0·54 (0·28–1·04) | n.s. | n.s. |
| p210 IgM | 0·64 (0·42–0·99) | 0·78 (0·53–1·07) | 0·03 | n.s. |
| MDA-p210 IgM | 0·80 (0·51–1·02) | 0·54 (0·28–1·04) | n.s. | n.s. |
| p210 IgG | 0·32 (0·10–0·64) | 0·50 (0·25–0·88) | 0·004 | n.s. |
| MDA-p210 IgG | 0·60 (0·3–0·84) | 0·72 (0·53–1·00) | 0·001 | 0·05 |
| Apo H antibodies | ||||
| β2GPI IgM | 1·9 (1·9–3·5) | 1·9 (1·9–4·0) | n.s. | n.s. |
| β2GPI IgG | 4·0 (1·9–30·9) | 1·9 (1·9–8·7) | 0·02 | 0·01 |
*
Distributions are given as median [interquartile range (IQR)]. Ig = immunoglobulin; MDA = malondialdehyde; CVD = cardiovascular disease; n.s. = not significant.